Clinical Trial Results of New Agent for Myelodysplastic Syndromes and Acute Myeloid Leukemia

0 Views
administrator
administrator
07/04/23

Raoul Tibes, M.D., Ph.D., hematologist and scientist at Mayo Clinic in Arizona, discusses Phase I clinical trial results of a new agent, SGI-110, a DNA hypomethylating agent, for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The results were presented at the American Association for Cancer Research (AACR) Annual Meeting 2012.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next